Back to top
more

ALPS Medical Breakthroughs ETF: (SBIO)

(Delayed Data from NYSE) As of May 7, 2024 03:53 PM ET

$34.90 USD

34.8972
3,585

+0.31 (0.89%)

Volume: 3,585

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

Zacks News

Sweta Killa headshot

Biotech ETFs Surge on Biogen's Alzheimer Drug Approval

The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.

Sweta Killa headshot

5 Small-Cap ETFs at the Forefront of the 2021 Market Rally

We have presented five ETFs that are easily crushing the Russell 2000 Index this year and are likely to continue their strong performance at least in the near term.

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

Sweta Killa headshot

5 Small-Cap Sector ETFs Beating the Russell 2000

We have presented five ETFs that have easily crushed the Russell 2000 Index over the past three months.

Sweta Killa headshot

Biotech ETF (SBIO) Hits a New 52-Week High

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Sanghamitra Saha headshot

Can Small-Cap ETFs Keep Up the Winning Trend in November?

The month of October was downbeat for Wall Street due to election uncertainty, failed stimulus talks, subdued tech earnings and rising coronavirus cases on the global front.

Sweta Killa headshot

5 Sector ETFs That Showed Strength Despite the Worst October

Wall Street registered its first back-to-back monthly loss of this year, with Dow Jones closing out the worst month since March.

Sweta Killa headshot

Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal

These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.

Sweta Killa headshot

New GERM ETF Launched to Tap the Growing Biotech Sector

GERM invests in the hottest emerging biotechnology trends.

Sanghamitra Saha headshot

Don't "Bet Against the American Economy:" ETF Areas to Win

Fed Chair Powell expressed optimism about the U.S. economic recovery over the long term. These ETF areas should benefit ahead.

    Sanghamitra Saha headshot

    Follow Warren Buffett With 5 ETF Strategies & Tackle COVID-19

    Follow Warren Buffett???s latest COVID-19-fighting tips with these ETF strategies.

    The Zacks Analyst Blog Highlights: SGDJ, PKB, SBIO and TAN

    The Zacks Analyst Blog Highlights: SGDJ, PKB, SBIO and TAN

    Sanghamitra Saha headshot

    Bet on "American Magic" With 4 Solid Small-Cap Sector ETFs

    These small-cap sector ETFs have put a great show in the past month and are likely to fare better in the post-lockdown period.

    Sweta Killa headshot

    First-Mover Pandemic Disease Fight ETF On The Way

    Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

    Sanghamitra Saha headshot

    Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

    Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

    Sanghamitra Saha headshot

    4 Sector ETFs That Beat the Market in Q4

    While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.

    Sweta Killa headshot

    Biotech Leading in Q4: Best ETFs & Stocks

    We highlight five biotech ETFs and stocks that are leading the market in Q4.

    Sanghamitra Saha headshot

    Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

    Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

    Sanghamitra Saha headshot

    5 ETF Areas Up At Least 45% in 2019

    These ETF areas crushed the S&P 500 in 2019.

    Sanghamitra Saha headshot

    Beyond Biotech, 5 ETFs Up At Least 10% in Q4

    Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.

    Neena Mishra headshot

    Why Biotech ETFs are Surging to New Highs

    increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

    Sweta Killa headshot

    Biotech ETFs Hit New Highs on Deal Activities

    Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

    Sweta Jaiswal, FRM headshot

    A Guide to Biotech ETF Investing

    Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.